Top

Published in:

01-04-2019 | Pictorial essay

Overview of systemic treatment in recurrent and advanced cervical cancer: a primer for radiologists

Authors: Colin Marshall, Maharshi A. Rajdev, Bhanusupriya Somarouthu, Nikhil H. Ramaiya, Francesco Alessandrino

Published in: Abdominal Radiology | Issue 4/2019

Abstract

Imaging has a central role in surveillance of cervical cancer, guiding decision on when to initiate treatment for recurrent disease and to guide management in advanced cervical cancer. Due to the increased availability of pelvic radiation therapy, the rate of atypical presentation of recurrent disease has increased. Simultaneously, the array of systemic therapies now available for advanced cervical cancer has considerably expanded in the last few years, with therapies now available in mid and low-income countries. While pelvic recurrences are amenable of loco-regional treatment, recurrent disease may present with metastases to the thoracoabdominal organs, lymph nodes, bones, skin and brain, for which systemic treatment represent the standard of care. Besides combined chemotherapy regimens, alternative chemotherapies, biosimilars and immune checkpoint inhibitors are now available, each associated with a definite pattern of response and toxicity. In this review, after describing the typical and atypical presentations of recurrent and advanced cervical carcinoma on cross-sectional imaging, we will discuss systemic treatment for recurrent or advanced disease and their associated radiographic sequelae, in light of the newly available therapies.

American Cancer Society. Global burden of cancer in women (2018) Current status, trends, and interventions. Atlanta: American Cancer Society; 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-burden-of-cancer-in-women.pdf. Accessed 18 July 2018

Adegoke O, Kulasingam S, Virnig B (2002) Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health 21(10):1031–1037CrossRef

Fagundes H, Perez CA, Grigsby PW, Lockett M (1992) Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol 24(2):197–204CrossRef

Elit L, Fyles AW, Devries MC, et al. (2009) Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 114(3):528–535CrossRefPubMed

Peiretti M, Zapardiel I, Zanagnolo V, et al. (2012) Management of recurrent cervical cancer: a review of the literature. Surg Oncol 21(2):e59–e66CrossRefPubMed

Sreedevi A, Javed R, Dinesh A (2015) Epidemiology of cervical cancer with special focus on India. Int J Womens Health 7:405–414PubMedCentralPubMed

LaVigne AW, Triedman SA, Randall TC, Trimble EL, Viswanathan AN (2017) Cervical cancer in low and middle income countries: addressing barriers to radiotherapy delivery. Gynecol Oncol Rep 22:16–20PubMedCentralCrossRefPubMed

Charakorn C, Thadanipon K, Chaijindaratana S, et al. (2018) The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: a systematic review and meta-analysis. Gynecol Oncol 150(1):190–200CrossRefPubMed

Quinn MA, Benedet JL, Odicino F, et al. (2006) Carcinoma of the cervix uteri. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(S1):S43–103CrossRefPubMed

10.

Kim TH, Kim MH, Kim BJ, et al. (2017) Prognostic importance of the site of recurrence in patients with metastatic recurrent cervical cancer. Int J Radiat Oncol 98(5):1124–1131CrossRef

11.

Fulcher AS, O’Sullivan SG, Segreti EM, Kavanagh BD (1999) Recurrent cervical carcinoma: typical and atypical manifestations. RadioGraphics 19(S1):S103–S116CrossRefPubMed

12.

Son H, Kositwattanarerk A, Hayes MP, et al. (2010) PET/CT evaluation of cervical cancer: spectrum of disease. Radiographics 30(5):1251–1268CrossRefPubMed

13.

Kavanagh BD, Gieschen HL, Schmidt-Ullrich RK, et al. (1997) A pilot study of concomitant boost accelerated superfractionated radiotherapy for stage III cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 38(3):561–568CrossRefPubMed

14.

Boussios S, Seraj E, Zarkavelis G, et al. (2016) Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review. Crit Rev Oncol Hematol 108:164–174CrossRefPubMed

15.

Monk BJ, Huh WK, Rosenberg JA, Jacobs I (2017) Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers? Gynecol Oncol Res Pract 4:7PubMedCentralCrossRefPubMed

16.

U. S. Food and Drug Administration/Center for Drug Evaluation and Research (2018) FDA approves first biosimilar for cancer treatment. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm576096.htm. Accessed 18 July 2018

17.

FIGO Committee on Gynecologic Oncology (2014) FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet 125(2):97–98CrossRef

18.

Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH (2003) Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 44(3):347–352PubMed

19.

Tirumani SH, Baez JC, Jagannathan JP, Shinagare AB, Ramaiya NH (2013) Tumor-bowel fistula: what radiologists should know. Abdom Imaging 38(5):1014–1023CrossRefPubMed

20.

Sotto LSJ, Graham JB, Pickren JW (1960) Postmortem findings in cancer of the cervix: an analysis of 108 autopsies in the past 5 years. Am J Obstet Gynecol 80(4):791–794CrossRef

21.

Choi HJ, Roh JW, Seo SS, et al. (2006) Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer 106(4):914–922CrossRefPubMed

22.

Wang H, Li QK, Auster M, Gong G (2018) PET and CT features differentiating infectious/inflammatory from malignant mediastinal lymphadenopathy: a correlated study with endobronchial ultrasound-guided transbronchial needle aspiration. Radiol Infect Dis 5(1):7–13CrossRefPubMedPubMedCentral

23.

Sugawara Y, Eisbruch A, Kosuda S, et al. (1999) Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 40(7):1125–1131PubMed

24.

Jeong YY, Kang HK, Chung TW, Seo JJ, Park JG (2003) Uterine cervical carcinoma after therapy: CT and MR imaging findings. RadioGraphics 23(4):969–981CrossRefPubMed

25.

Badib AO, Kurohara SS, Webster JH, Pickren JW (1968) Metastasis to organs in carcinoma of the uterine cervix. Cancer 21:434–439CrossRefPubMed

26.

Flynn VT, Spurrett BR (1969) Sister Joseph’s nodule. Med J Aust 1:728–730PubMed

27.

Avdalovic M, Chan A (2004) Thoracic manifestations of common nonpulmonary malignancies of women. Clin Chest Med 25(2):379–390CrossRefPubMed

28.

Li H, Wu X, Cheng X (2016) Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol 27(4):e43PubMedCentralCrossRefPubMed

29.

Martínez-Jiménez S, Rosado-de-Christenson ML, Walker CM, et al. (2014) Imaging features of thoracic metastases from gynecologic neoplasms. Radiographics 34(6):1742–1754CrossRefPubMed

30.

National Comprehensive Cancer Network (2018) Cervical cancer. Version 2.2018. https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed 18 July 2018

31.

Kumar R, Gupta R, Khullar S, et al. (2000) Bone scanning for bone metastasis in carcinoma cervix. J Assoc Phys India 48(8):808–810

32.

du Toit JP, Grove DV (1987) Radioisotope bone scanning for the detection of occult bony metastases in invasive cervical carcinoma. Gynecol Oncol 28(2):215–219CrossRefPubMed

33.

Hirnle P, Mittmann KP, Schmidt B, Pfeiffer KH (1990) Indications for radioisotope bone scanning in staging of cervical cancer. Arch Gynecol Obstet 248(1):21–23CrossRefPubMed

34.

Chura JC, Shukla K, Argenta PA (2007) Brain metastasis from cervical carcinoma. Int J Gynecol Cancer 17(1):141–146CrossRefPubMed

35.

Cormio G, Pellegrino A, Landoni F, et al. (1996) Brain metastases from cervical carcinoma. Tumori 82(4):394–396CrossRefPubMed

36.

Piura E, Piura B (2012) Brain metastases from cervical carcinoma: overview of pertinent literature. Eur J Gynaecol Oncol 33(6):567–573PubMed

37.

Fetcko K, Gondim DD, Bonnin JM, Dey M (2017) Cervical cancer metastasis to the brain: a case report and review of literature. Surg Neurol Int 8:181PubMedCentralCrossRefPubMed

38.

Malviya VK, Casselberry JM, Parekh N, Deppe G (1990) Pericardial metastases in squamous cell cancer of the cervix: a report of two cases. J Reprod Med 35(1):49–52PubMed

39.

Pannu HK, Corl FM, Fishman EK (2001) CT evaluation of cervical cancer: spectrum of disease. Radiographics 21(5):1155–1168CrossRefPubMed

40.

Chuang LT, Temin S, Camacho R, et al. (2016) Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline. J Glob Oncol 2(5):311–340PubMedCentralCrossRefPubMed

41.

Monk BJ, Tewari KS (2014) Evidence-based therapy for recurrent cervical cancer. J Clin Oncol 32(25):2687–2690CrossRefPubMed

42.

Monk BJ, Sill MW, McMeekin DS, et al. (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27(28):4649–4655PubMedCentralCrossRefPubMed

43.

Tewari KS, Sill MW, Long HJ, et al. (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370(8):734–743PubMedCentralCrossRefPubMed

44.

U. S. Food and Drug Administration/Center for Drug Evaluation and Research (2014) Avastin (bevacizumab). Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s301lbl.pdf. Accessed 18 July 2018

45.

U. S. Food and Drug Administration/Center for Drug Evaluation and Research (2018) FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm. Accessed 18 July 2018

46.

Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378CrossRefPubMedPubMedCentral

47.

Rosenberg B, Camp LV, Krigas T (1965) Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature 205(4972):698–699CrossRefPubMed

48.

Bonomi P, Blessing JA, Stehman FB, et al. (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3(8):1079–1085CrossRefPubMed

49.

King PD, Perry MC (2001) Hepatotoxicity of chemotherapy. Oncologist 6(2):162–176CrossRefPubMed

50.

Trivedi CD, Pitchumoni CS (2005) Drug-induced pancreatitis: an update. J Clin Gastroenterol 39(8):709–716CrossRefPubMed

51.

Torrisi JM, Schwartz LH, Gollub MJ, et al. (2011) CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258(1):41–56CrossRefPubMed

52.

Rohatgi S, Jagannathan JP, Rosenthal MH, et al. (2014) Vascular toxicity associated with chemotherapy and molecular targeted therapy: what should a radiologist know? AJR 203(6):1353–1362CrossRefPubMed

53.

Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C (1999) Topotecan: a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56(1):1–12CrossRefPubMed

54.

Long HJ, Bundy BN, Grendys EC, et al. (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 23(21):4626–4633CrossRefPubMed

55.

Pubchem (2018) Topotecan. https://pubchem.ncbi.nlm.nih.gov/compound/60700. Accessed 18 May 2018

56.

Rodrigues FG, Dasilva G, Wexner SD (2017) Neutropenic enterocolitis. World J Gastroenterol 23(1):42–47PubMedCentralCrossRefPubMed

57.

Maitland ML, Wilcox R, Hogarth DK, et al. (2006) Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer 54(2):243–245CrossRefPubMed

58.

Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. RadioGraphics 20(5):1245–1259CrossRefPubMed

59.

Edgerton CC, Gilman M, Roth BJ (2004) Topotecan-induced bronchiolitis. South Med J 97(7):699–701CrossRefPubMed

60.

Horwitz SB (1994) Taxol (paclitaxel): mechanisms of action. Ann Oncol 5(S6):S3–S6PubMed

61.

Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M (2015) Paclitaxel and its evolving role in the management of ovarian cancer. BioMed Res Int 2015:413076PubMedCentralCrossRefPubMed

62.

Moore DH, Blessing JA, McQuellon RP, et al. (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22(15):3113–3119CrossRefPubMed

63.

Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20(4S3):1–15PubMed

64.

Bielopolski D, Evron E, Moreh-Rahav O, et al. (2017) Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J Chemother 29(2):113–117CrossRefPubMed

65.

Tamiya A, Naito T, Miura S, et al. (2012) Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res 32(3):1103–1106PubMed

66.

Capasso A (2012) Vinorelbine in cancer therapy. Curr Drug Targets 13(8):1065–1071CrossRefPubMed

67.

Morris M, Brader KR, Levenback C, et al. (1998) Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 16(3):1094–1098CrossRefPubMed

68.

Muggia FM, Blessing JA, Method M, et al. (2004) Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 92(2):639–643CrossRefPubMed

69.

Gregory RK, Smith IE (2000) Vinorelbine: a clinical review. Br J Cancer 82(12):1907–1913PubMedCentralCrossRefPubMed

70.

Plunkett W, Huang P, Xu YZ, et al. (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(4S11):3–10PubMed

71.

Mutch DG, Bloss JD (2003) Gemcitabine in cervical cancer. Gynecol Oncol 90:S8–S15CrossRefPubMed

72.

Chi D-C, Brogan F, Turenne I, et al. (2012) Gemcitabine-induced pulmonary toxicity. Anticancer Res 32(9):4147–4149PubMed

73.

Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28(11):1779–1802CrossRefPubMed

74.

Krill LS, Tewari KS (2015) Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer. Expert Opin Pharmacother 16(5):675–683CrossRefPubMed

75.

Tirumani SH, Fairchild A, Krajewski KM, et al. (2015) Anti-VEGF molecular targeted therapies in common solid malignancies: comprehensive update for radiologists. Radiographics 35(2):455–474CrossRefPubMed

76.

Howard SA, Krajewski KM, Thornton E, et al. (2012) Decade of molecular targeted therapy: abdominal manifestations of drug toxicities—what radiologists should know. AJR 199(1):58–64CrossRefPubMed

77.

Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH (2013) Liver metastases in the era of molecular targeted therapy: new faces of treatment response. AJR 201(1):W15–W28CrossRefPubMed

78.

Odia Y, Shih JH, Kreisl TN, Fine HA (2014) Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. J Neurooncol 120(2):431–440CrossRefPubMed

79.

Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105(1):3–6CrossRefPubMed

80.

Singh J, Steward M, Booth T, Mukhtar H, Murray D (2010) Evolution of imaging for abdominal perforation. Ann R Coll Surg Engl 92(3):182–188PubMedCentralCrossRefPubMed

81.

Hang XF, Xu WS, Wang JX, et al. (2011) Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 67(6):613–623CrossRefPubMed

82.

Tirumani SH, Jagannathan JP, Shinagare AB, et al. (2013) Acute pancreatitis associated with molecular targeted therapies: a retrospective review of the clinico-radiological features, management and outcome. Pancreatology 13(5):461–467CrossRefPubMed

83.

Tirumani SH, Krajewski KM, Shinagare AB, Jagannathan JP, Ramaiya NH (2014) Gallbladder complications associated with molecular targeted therapies: clinical and imaging features. Clin Imaging 38(1):50–55CrossRefPubMed

84.

Wolford JE, Tewari KS (2017) Highlights from the gynecologic oncology track at the 2017 Annual Meeting of the American Society of Clinical Oncology. J Gynecol Oncol 28(5):e74PubMedCentralCrossRefPubMed

85.

Hollebecque A, Meyer T, Moore KN, et al. (2017) An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J Clin Oncol 35(15S):5504CrossRef

86.

Schellens JH, Marabelle A, Zeigenfuss S, et al. (2017) Pembrolizumab for previously treated advanced cervical squamous cell cancer: preliminary results from the phase 2 KEYNOTE-158 study. J Clin Oncol 35:5514CrossRef

87.

Wolchok JD, Hoos A, O’Day S, et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420CrossRefPubMed

88.

Naidoo J, Page DB, Li BT, et al. (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375–2391PubMedCentralPubMed

89.

Mekki A, Dercle L, Lichtenstein P, et al. (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91–104CrossRefPubMed

90.

Kim KW, Ramaiya NH, Krajewski KM, et al. (2013) Ipilimumab-associated colitis: CT findings. AJR 200(5):W468–474CrossRefPubMed

91.

Kim KW, Ramaiya NH, Krajewski KM, et al. (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31(4):1071–1077CrossRefPubMed

92.

Alessandrino F, Tirumani SH, Krajewski KM, et al. (2017) Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol 72(7):521–533CrossRefPubMed

93.

Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2(12):1607–1616CrossRefPubMed

94.

Gkiozos I, Kopitopoulou A, Kalkanis A, et al. (2018) Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2018.04.031 CrossRefPubMed

Title: Overview of systemic treatment in recurrent and advanced cervical cancer: a primer for radiologists
Authors: Colin Marshall
Maharshi A. Rajdev
Bhanusupriya Somarouthu
Nikhil H. Ramaiya
Francesco Alessandrino
Publication date: 01-04-2019
Publisher: Springer US
Published in: Abdominal Radiology / Issue 4/2019
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-018-1797-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Radiological patterns of secondary sclerosing cholangitis in patients after lung transplantation

Structured reporting of MRI for perianal fistula

The ringed esophagus

Association of advanced hepatic fibrosis and sonographic visualization score: a dual-center study using ACR US LI-RADS

Differentiation between inflammatory myofibroblastic tumor and cholangiocarcinoma manifesting as target appearance on gadoxetic acid-enhanced MRI

Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage